GCP inspection readiness means a clinical trial site can show, at any time, that the trial was run according to the protocol, Good Clinical Practice and local regulations, and that participants' rights, safety and data were protected. Inspectors test this by reviewing records and interviewing staff, so readiness depends on what is documented, not on what people remember.
An inspection can follow a marketing application, a complaint, a signal from monitoring data or a routine programme. A site that keeps its records inspection-ready from the first participant has far less to fix when the notification arrives.
Who inspects clinical trial sites
Inspections are carried out by regulators, not sponsors. In India, CDSCO can inspect sites under the New Drugs and Clinical Trials Rules, 2019. Sites in India and the GCC may also be inspected by foreign regulators, such as the US FDA or European authorities, when trial data support applications in those markets. In the GCC, national authorities such as the SFDA in Saudi Arabia have their own inspection programmes.
Sponsor audits are different, but good preparation for both looks much the same. Inspection procedures vary, so check the approach of the relevant authority.
What inspectors review
Inspectors usually follow a sample of participants from consent to their last visit, checking that what happened matches the protocol and that every data point can be traced to source. The main focus areas are:
- Informed consent: approved version, signed and dated before any trial procedure, re-consent after amendments
- Eligibility: source evidence for every inclusion and exclusion criterion
- Source data vs CRF: agreement, with audit trails for changes
- Safety reporting: AE capture and SAE reporting timelines
- Investigational product: storage, temperature, dispensing and accountability
- Delegation and oversight: tasks done only by trained, delegated staff under PI supervision
- Training: CVs, GCP and protocol training
- Essential records: a complete, version-controlled investigator site file
- Protocol deviations: identified, documented, reported and assessed
ICH E6(R3), finalised by ICH in 2025, uses the term essential records and places strong emphasis on investigator oversight and fitness of data for purpose. Our beginner's guide to ICH GCP E6(R3) covers the principles.
Site inspection readiness checklist
| Area | What inspectors check | Readiness action |
|---|---|---|
| Informed consent | Version, signatures, dates, timing, re-consent | Audit every consent form against version history and visit dates |
| Eligibility | Source evidence for each criterion | Prepare eligibility checklists with source references |
| Source and CRF | Agreement, legibility, audit trails | Reconcile a sample of data points; resolve open queries |
| Safety reporting | AE capture and SAE timelines | Compare AE logs with source notes; check SAE report dates |
| Investigational product | Accountability and storage temperature | Reconcile counts; review temperature logs and excursion handling |
| Delegation log | Tasks match training and dates | Check start and end dates against signatures in source |
| Training records | GCP and protocol training before tasks | File certificates and training logs for all delegated staff |
| Investigator site file | Completeness and current versions | Use the sponsor's ISF index and check each section |
| Ethics and regulatory | Approvals, amendments, correspondence | Confirm every document version used was approved |
| Protocol deviations | Logging, reporting and CAPA | Review the deviation log against monitoring reports |
Readiness activities before the inspection
Assign a coordinator, usually the study coordinator with QA support, and agree a plan with the principal investigator and sponsor.
- Confirm logistics: inspection dates, scope, trials and participants likely to be reviewed, and a suitable room.
- Review the ISF and source: check completeness, file loose documents and make sure electronic records are accessible.
- Reconcile key data: consent, eligibility, safety reporting and investigational product, as in the checklist.
- Correct properly: errors found during preparation should be corrected in line with ALCOA data integrity principles, with dated, attributable notes. Never back-date or re-create records.
- Prepare a site overview: a short presentation on the site, staff, facilities and the trial.
- Brief staff: everyone involved should know their role, where records are kept and how interviews work.
Run a mock inspection
A mock inspection by the sponsor, a CRO or an independent auditor is one of the most effective preparation steps. Ask the mock inspector to trace two or three participants from consent to last visit and to interview the principal investigator and coordinator. The findings show where real inspectors are likely to focus.
Interview tips for site staff
Inspectors interview the principal investigator, sub-investigators, coordinators, pharmacists and sometimes laboratory staff. Practical advice:
- answer the question asked, honestly and briefly
- say if you do not know, and offer to find the right person or record
- never guess, speculate or blame colleagues
- show the record rather than describing it from memory
- the principal investigator should be available and able to explain how they oversee the trial
Keep a log of every document requested and provided, and hold a short debrief with the team at the end of each day.
Common inspection findings
Themes reported repeatedly in regulators' public inspection material include inadequate investigator oversight, consent process failures, incomplete or inconsistent source records, delayed or missed safety reports, investigational product accountability gaps, and protocol deviations that were not identified or reported. Our guide to protocol deviations in clinical research explains how to manage the last of these.
Worked example: a Bengaluru site receives notice of an inspection
A multispecialty hospital in Bengaluru runs a Phase III cardiology trial for a global sponsor. The principal investigator receives notice that the regulator will inspect the site.
- Day 1: the PI informs the sponsor and ethics committee as required and names the senior study coordinator as inspection coordinator.
- ISF and consent review: the team checks every consent form. Two participants re-consented to an updated version after, not before, their next visit. Both were already logged and reported as deviations, and the records are filed together.
- Safety reconciliation: comparing outpatient notes with the AE log reveals one unrecorded mild adverse event. It is entered with a dated late-entry note and reported through the sponsor's process.
- Investigational product: pharmacy temperature logs show a weekend excursion in the storage refrigerator. The excursion report, sponsor assessment and approval to continue use are retrieved and filed.
- Mock interviews: the CRA runs practice interviews, and the PI prepares to explain how they oversee safety and delegated staff.
- During the inspection: requests are logged and answered promptly. After the closing meeting, the site prepares a CAPA response with the sponsor.
Nothing was hidden or re-written. The site's credibility came from showing that issues had been found and handled through its own processes.
Common mistakes
- Starting preparation only after the inspection notice arrives.
- Back-dating signatures or re-creating missing records.
- An unavailable or poorly briefed principal investigator.
- Delegation log entries that do not match who actually did the work.
- Unfiled sponsor and ethics committee correspondence.
- Staff guessing answers instead of checking records.
- Treating known deviations as something to conceal rather than show were managed.
Key takeaway: Inspection readiness is built visit by visit, not in the week before an inspection. Keep consent, eligibility, safety and investigational product records traceable, and make sure the principal investigator can show real oversight.
Frequently Asked Questions
What is a GCP inspection?
A GCP inspection is an official review by a regulatory authority of a clinical trial's documents, facilities, records and processes. Inspectors check whether the trial followed the protocol, Good Clinical Practice and applicable regulations, and whether participants' rights, safety and data were protected. Inspections can take place at sites, sponsors, CROs or laboratories.
What is the difference between a sponsor audit and a regulatory inspection?
A sponsor audit is carried out by or for the sponsor as part of its quality system, and findings are handled between the sponsor and the site. A regulatory inspection is carried out by an authority such as CDSCO, the SFDA or the US FDA, and its findings can affect the acceptability of trial data and lead to regulatory action.
How much notice does a site get before a GCP inspection?
It depends on the authority and the reason for the inspection. Routine inspections are often announced in advance, while inspections triggered by specific concerns may come with short notice. Practices differ between regulators and change over time, so sites should not rely on a fixed notice period and should keep records inspection-ready throughout the trial.
What documents should be in the investigator site file?
The investigator site file holds the site's essential records, such as the protocol and amendments, approved consent forms, ethics and regulatory approvals, delegation and training records, CVs, laboratory certifications, investigational product records, safety reports, monitoring correspondence and deviation logs. The sponsor usually provides an ISF index, and ICH E6(R3) describes essential records in more detail.
Next steps
To strengthen your site's inspection readiness, explore our Clinical Research & GCP Essentials course and Good Documentation Practices & Data Integrity Essentials. For related reading, see informed consent in clinical trials, risk-based clinical trial monitoring tips and protocol deviations in clinical research. You can also speak to a counsellor.
Looking for structured certification?
Explore Innoryx courses or speak to a counsellor about the right program for you.